GleamWall
中文EN

IBIO iBio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1420720 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY115.0%
TTM net income YoY-73.4%
TTM EPS YoY81.4%
Revenue 3-yr CAGR178.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,491.0%
Net margin-3,244.2%
FCF margin-2,566.3%
EBITDA margin-3,437.0%

Returns

ROE-51.8%
ROA-45.6%
ROIC (approx.)-97.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue60.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q3*2026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$1.07M$0$0$0$100,000$200,000$0$200,000
R&D expense$6.65M$8.56M$3.25M$4.28M$3.55M$3.22M$1.91M$1.88M
SG&A expense$2.76M-$2.18M$5.11M$5.17M$2.50M$2.17M$2.97M$2.74M
Operating income-$8.34M-$11.38M-$8.37M-$9.45M-$5.95M-$5.20M-$4.88M-$4.42M
Interest expense—-$46,000$22,000$41,000$34,000$44,000$54,000$57,000
Pretax income-$7.55M———-$5.72M———
Income tax$0$0$0$0$0$0$0$0
Net income-$7.55M-$10.60M-$7.73M-$8.99M-$5.72M-$5.16M-$4.86M-$4.36M
EBITDA-$8.19M-$11.23M-$8.22M-$9.30M-$5.83M-$5.08M-$4.76M-$4.30M
EPS (basic)-0.05—-0.06-0.09-0.11—-0.49-0.48
EPS (diluted)-0.05—-0.06-0.09-0.11—-0.49-0.48
Weighted avg. shares (diluted)151.57M—119.60M99.13M52.98M—9.86M9.13M
Balance sheet
Cash & equivalents$45.44M$56.40M$47.63M$28.67M$28.34M$8.79M$5.18M$7.24M
Short-term investments$31.22M$31.64M$27.19M$24.02M$21.47M$0——
Receivables$125,000———$65,000$0——
Current assets$81.24M$92.22M$77.25M$53.37M$50.77M$9.72M$6.06M$8.29M
PP&E, net$3.02M$3.09M$3.31M$3.45M$3.21M$3.16M$3.28M$3.39M
Intangibles$2.57M$1.82M$1.83M$4.34M$6.84M$6.85M$6.10M$6.11M
Total assets$88.65M$99.11M$85.83M$64.39M$64.16M$23.18M$19.10M$21.70M
Current liabilities$8.57M$11.74M$6.50M$5.90M$6.05M$6.11M$5.40M$4.71M
Total liabilities$10.08M$13.40M$8.30M$7.83M$8.12M$8.30M$7.72M$7.80M
Shareholders' equity$78.57M$85.71M$77.54M$56.56M$56.04M$14.88M$11.38M$13.89M
Shares outstanding64.31M55.70M34.54M30.05M20.25M19.35M10.07M9.17M
Cash flow statement
Operating cash flow-$9.39M-$6.23M-$6.08M-$5.24M-$5.67M-$4.62M-$3.10M-$3.87M
Capital expenditure$102,000$19,000$11,000$516,000$32,000$1,000$14,000$1,000
Free cash flow-$9.49M-$6.25M-$6.09M-$5.76M-$5.70M-$4.62M-$3.12M-$3.87M
Investing cash flow-$454,000-$4.41M-$3.11M-$2.98M-$21.49M$45,000-$14,000-$2,000
Financing cash flow-$1.12M$19.40M$28.15M$8.79M$46.70M$8.18M$1.06M-$152,000
Depreciation & amortization$145,000$147,000$147,000$141,000$123,000$121,000$121,000$122,000
Stock-based compensation$435,000$420,000$377,000$253,000$323,000$270,000$370,000$475,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.